Expertise in
9
conditions

Dr. Kathryn Kolibaba

Oncology
Northwest Cancer Specialists PC
210 SE 136th Ave, 
Vancouver, WA 
Expertise in
9
conditions
Northwest Cancer Specialists PC
210 SE 136th Ave, 
Vancouver, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathryn Kolibaba is an Oncologist in Vancouver, Washington. Dr. Kolibaba is highly rated in 9 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Her clinical research consists of co-authoring 18 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Northwest Cancer Specialists PC
210 SE 136th Ave, Vancouver, WA 98684

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drugs: Obinutuzumab, Bendamustine, Venetoclax
Study Phase: Phase 3
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drugs: Brentuximab, Bendamustine, Dacarbazine, Nivolumab
Study Phase: Phase 2
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant
Enrollment Status: Completed
Publish Date: November 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

18 Total Publications

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Journal: Neuro-oncology advances
Published: May 31, 2021
Similar Doctors
Brendan D. Curti
Expertise in
14
conditions
Dr. Brendan D. Curti
Oncology
Expertise in
14
conditions
Dr. Brendan D. Curti
Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (7.4 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Brendan Curti is an Oncologist in Portland, Oregon. Dr. Curti is highly rated in 14 conditions, according to our data. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Expertise in
12
conditions
Dr. Rachel E. Sanborn
Oncology
Expertise in
12
conditions
Dr. Rachel E. Sanborn
Oncology
4805 Northeast Glisan Street, Suite 11N-1, 
Portland, OR 
 (7.4 miles away)
503-215-5696
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rachel Sanborn is an Oncologist in Portland, Oregon. Dr. Sanborn is highly rated in 12 conditions, according to our data. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration. Dr. Sanborn is currently accepting new patients.

Expertise in
4
conditions
Dr. Michael Recht
Hematology | Oncology
Expertise in
4
conditions
Dr. Michael Recht
Hematology | Oncology

Doernbecher Children's Hospital

700 SW Campus Dr, 
Portland, OR 
 (11.2 miles away)
503-494-8716
Languages Spoken:
English
See accepted insurances

Michael Recht is a Hematologist and an Oncologist in Portland, Oregon. Dr. Recht is highly rated in 4 conditions, according to our data. His top areas of expertise are Hemophilia A, Blood Clots, Hemophilia B, Von Willebrand Disease (VWD), and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kolibaba's expertise for a condition
ConditionClose
    View All 41 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile